Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Ball

Showing results (421-430 of 449) with videos related to

Pageof 45
Sort By:
MMWR. Morbidity and Mortality Weekly Report|December 11, 2025
Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025Stephanie A Irving, Elizabeth A K Rowley, Sean Chickery, et al.
JAMA Network Open|June 23, 2026
Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative DesignRyan E Wiegand, Sean Chickery, Duck-Hye Yang, et al.
MMWR. Morbidity and Mortality Weekly Report|August 17, 2023
Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023Ruth Link-Gelles, Allison Avrich Ciesla, Elizabeth A K Rowley, et al.
MMWR. Morbidity and Mortality Weekly Report|March 28, 2024
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024Ruth Link-Gelles, Elizabeth A K Rowley, Malini B DeSilva, et al.
Lancet Regional Health. Americas|June 19, 2023
Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort studyKatherine Adams, John J Riddles, Elizabeth A K Rowley, et al.
Lancet Regional Health. Americas|October 3, 2025
Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysisAmanda B Payne, Steph Battan-Wraith, Elizabeth A K Rowley, et al.
JAMA Network Open|June 25, 2025
Estimated 2023-2024 COVID-19 Vaccine Effectiveness in AdultsRuth Link-Gelles, Elizabeth A K Rowley, Stephanie A Irving, et al.
MMWR. Morbidity and Mortality Weekly Report|December 29, 2022
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022Mark W Tenforde, Zachary A Weber, Karthik Natarajan, et al.
Lancet (London, England)|October 19, 2024
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysisAmanda B Payne, Janet A Watts, Patrick K Mitchell, et al.
Influenza and Other Respiratory Viruses|March 17, 2024
Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric DisordersMatthew E Levy, Duck-Hye Yang, Margaret M Dunne, et al.
Pageof 45

Showing results (421-430 of 449) with videos related to

Sort By:
Pageof 45
MMWR. Morbidity and Mortality Weekly Report|December 11, 2025
Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025Stephanie A Irving, Elizabeth A K Rowley, Sean Chickery, et al.
JAMA Network Open|June 23, 2026
Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative DesignRyan E Wiegand, Sean Chickery, Duck-Hye Yang, et al.
MMWR. Morbidity and Mortality Weekly Report|August 17, 2023
Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023Ruth Link-Gelles, Allison Avrich Ciesla, Elizabeth A K Rowley, et al.
MMWR. Morbidity and Mortality Weekly Report|March 28, 2024
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024Ruth Link-Gelles, Elizabeth A K Rowley, Malini B DeSilva, et al.
Lancet Regional Health. Americas|June 19, 2023
Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort studyKatherine Adams, John J Riddles, Elizabeth A K Rowley, et al.
Lancet Regional Health. Americas|October 3, 2025
Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysisAmanda B Payne, Steph Battan-Wraith, Elizabeth A K Rowley, et al.
JAMA Network Open|June 25, 2025
Estimated 2023-2024 COVID-19 Vaccine Effectiveness in AdultsRuth Link-Gelles, Elizabeth A K Rowley, Stephanie A Irving, et al.
MMWR. Morbidity and Mortality Weekly Report|December 29, 2022
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022Mark W Tenforde, Zachary A Weber, Karthik Natarajan, et al.
Lancet (London, England)|October 19, 2024
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysisAmanda B Payne, Janet A Watts, Patrick K Mitchell, et al.
Influenza and Other Respiratory Viruses|March 17, 2024
Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric DisordersMatthew E Levy, Duck-Hye Yang, Margaret M Dunne, et al.
Pageof 45